List of Definity drug patents

Definity is owned by Lantheus Medcl.

Definity contains Perflutren.

Definity has a total of 8 drug patents out of which 0 drug patents have expired.

Definity was authorised for market use on 31 July, 2001.

Definity is available in injectable;intravenous dosage forms.

Definity can be used as method of using the drug substance/drug product for ultrasound imaging.

The generics of Definity are possible to be released after 04 May, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10022460 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(12 years from now)

US11395856 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583207 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(12 years from now)

US10583208 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(14 years from now)

US11529431 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(14 years from now)

US11266750 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(14 years from now)

US9789210 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(14 years from now)

US10588988 LANTHEUS MEDCL Methods and devices for preparation of ultrasound contrast agents
May, 2037

(14 years from now)

Drugs and Companies using PERFLUTREN ingredient

Market Authorisation Date: 31 July, 2001

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic